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Abstract 
CEACAM19 is a member of the CEACAM 
subfamily of genes, described for the first time by 
Scorilas et al. (2003). Very few studies have been 
conducted so far concerning the CEACAM19 gene. 
Consequently, very little is known about it, and its 
function in either physiological or pathological 
cellular processes remains poorly elucidated. Here, 
we present a review on the DNA, mRNA and protein 
level of the gene and on its implication in various 
types of human malignancies. 
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Identity 
Other names 
CEACM19, CEAL1 
HGNC (Hugo): CEACAM19 
Location: 19q13.31 
Local order: Centromere to telomere 
DNA/RNA 
Description 
The CEACAM19 gene belongs to the CEACAM 
subfamily of the CEA gene family, which in turn 
belongs to the Immunoglobulin Superfamily (IgS) 
(Scorilas et al., 2003). It has a total length of 12,904 
nucleotides and consists of 8 exons and 7 intervening 
introns (Scorilas et al., 2003). It is located 
downstream of the PVR gene (poliovirus receptor 
cell adhesion molecule) and upstream of the 
CEACAM16 gene at the chromosomal location 
19q13.31. 
Transcription 
CEACAM19 pre-mRNA is subjected to alternative 
splicing. According to UniProt, three main splice 
variants of the gene have been described. The first 
one, which is referred to as the "canonical" one, 
consists of 903 nt and encodes for a 300-amino-acid 
(aa) polypeptide chain (Scorilas et al., 2003). The 
second splice variant contains one more exon (exon 
3) of 134 bp and encodes for a polypeptide chain of
142 aa residues (Scorilas et al., 2003). The third 
splice variant consists of 900 nt and encodes for a 
polypeptide chain of 299 aa residues. However, 
according to the Human Protein Atlas, another five 
splice variants have also been described. 
Pseudogene 
Not identified so far. 
Protein 
Description 
The canonical polypeptide isoform that is encoded 
by the CEACAM19 gene (isoform 1) consists of 300 
aa residues and has a putative molecular weight of 
32.6 kDa. (Scorilas et al., 2003). This polypeptide 
corresponds to a protein with an N-terminal 
extracellular domain consisting of the aa residues 
33-157 and one Ig-like helical transmembrane 
domain, similar to other members of the same gene 
family (CEA family), composed of the aa residues 
158-178 (Scorilas et al., 2003). The protein carries a 
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hydrophobic N-terminal sequence, which is thought 
to act as a signal peptide and which is comprised on 
its whole of the aa residues 1-32 (Scorilas et al., 
2003). The signal peptide of the protein is removed. 
aa residues 179-300 represent the cytoplasmic part 
of this protein (Figure 1). The CEACAM19 protein 
bears no constant C2-like domains like the ones seen 
in other members of the same family (Beauchemin 
et al., 2013). The protein bears a 9-aa sequence 
(SAMGQRDIV - from position 92 to 100) that is 
present in the eIF5A domain of a variety of 
transcription factors in eukaryotes (Scorilas et al., 
2003). Moreover, the CEACAM19 polypeptide is a 
heavily glycosylated glycoprotein, which carries an 
ITAM motif (Immunoreceptor Tyrosine-based 
Activation Motif) in its cytoplasmic tail (as most of 
the members of the same subfamily) (Beauchemin et 
al., 2013). Moreover, several putative sites for post-
translational modifications, such as O-/N-
glycosylation, phosphorylation, N-myristoylation, 
have been described (Scorilas et al., 2003).  
The alternative splicing of CEACAM19 pre-mRNA 
leads to the production of two other protein isoforms. 
As described previously, the second splice variant 
encodes for a polypeptide of 142 aa residues, shorter 
than the one described as the canonical form of the 
protein. Besides the fact that the aa residues from 
position 143 to 300 are missing, this isoform also 
differs from the canonical one in that the glutamic 
acid residue in position 142 is replaced by an aspartic 
acid residue. The third  
protein isoform is derived from a splice variant of 
900 nt and consists of 299 aa residues. In this case, 
the glutamine residue in position 282 of the 
canonical form is missing.  
As described above, the Human Protein Atlas 
mentions the existence of another five splice variants 
of the CEACAM19 gene, which encode for secreted 
polypeptides and not transmembrane ones (contrary 
to the three main isoforms described earlier). Four of 
these polypeptides consist of 56 aa residues and 
share a common molecular weight of 6.1 kDa each, 
while one of them consists of 54 amino acids and has 
a molecular weight of 6 kDa. All these polypeptide 
chains bear a signal peptide consisting of the amino 
acids 1-33. 
Expression 
The CEACAM19 gene is widely expressed in a 
variety of tissues. Based on RNA-seq experiments 
(Fagerberg et al., 2014), higher expression levels are 
mainly seen in skin and testis. However, moderate to 
high expression levels have also been described in 
the prostate, adrenal gland, endometrium, lung, and 
ovary. 
Localisation 
The three main CEACAM19 protein isoforms that 
bear a transmembrane domain are characterized as 
single-pass type-I membrane proteins. These are 
proteins that traverse the membrane only once with 
their N-terminal domain on the extracellular side of 
it and their signal peptide being removed. 
 
Figure 1. Alignment of the three main protein isoforms (CLUSTAL O 1.2.4) that arise as a result of the CEACAM19 pre-mRNA 
alternative splicing procedure. The N-terminal signal peptide and the eIF5A domain that are present in all three protein isoforms 
are shown in red and light blue, respectively. The Ig-like transmembrane domain is underlined. The ITAM motif present in the two 
of the three isoforms is shown in green 
.
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However, according to the Human Protein Atlas, the 
rest of the protein isoforms, which lack 
transmembrane domains, are predicted to be 
secreted. 
Function 
The functions of the CEACAM19 protein (either 
physiological or pathological) have not been 
elucidated, yet. 
Implicated in 
Ovarian cancer 
Prognosis 
CEACAM19 mRNA expression is higher in ovarian 
cancer tissues, particularly in patients with late stage 
(stage III) of the disease and patients having been 
subjected to suboptimal cytoreduction. The sizes of 
the residual tumors were found to present a 
statistically significant difference between 
CEACAM19 mRNA-positive and -negative tumors, 
with the positive ones exhibiting larger dimensions. 
No statically significant association has been 
observed between the expression status of 
CEACAM19 and patients' age (Scorilas et al., 2003). 
Breast cancer 
Prognosis 
CEACAM19 has been shown to be overexpressed in 
malignant breast tissue sections, compared to normal 
counterparts derived from the same patients 
(Michaelidou et al., 2013), and in breast tumor 
samples compared to samples derived from normal 
individuals (Estiar et al., 2016). Furthermore, higher 
mRNA levels of CEACAM19 have been associated 
with increased risk of breast cancer in women. The 
association between CEACAM19 mRNA 
expression and various clinicopathological 
parameters linked to aggressive tumor behavior and 
poor prognosis has also been examined in the 
aforementioned study. In particular, elevated 
expression levels have been observed in higher grade 
(grade III) tumors and those with a high proliferation 
index. Moreover, it has been shown that the 
expression of CEACAM19 is elevated in estrogen 
receptor (ER)-negative tumors and those of 
premenopausal patients; both these features are 
associated with poor prognosis (Michaelidou et al., 
2013). On the other hand, another study by Estiar et 
al. (2016) did not support the positive association 
between CEACAM19 expression and tumor grade, 
observed by Michaelidou et al. (2013), as described 
above. In the study of Estiar et al., no significant 
association was shown between CEACAM19 
mRNA expression status and tumor grade. 
Moreover, the study of Estiar et al. revealed a 
statistically significant difference in the expression 
of CEACAM19 between ER/PR-positive and -
negative breast cancer patients, with higher mRNA 
levels in the latter (Estiar et al., 2016). 
Gastric cancer 
Prognosis 
It has been shown that CEACAM19 protein levels 
are significantly elevated in gastric cancer tissues 
and cancerous cell lines, compared to normal ones. 
Similarly, the same study showed that the expression 
of matrix metallopeptidases 2 and 9 ( MMP2 and 
MMP9) was also upregulated in gastric cancer cell 
lines and that knockdown of CEACAM19 via 
siRNA in the same cells led to the inhibition of their 
expression. Knockdown of CEACAM19 was also 
shown to lead to a decrease in proliferation, invasion, 
and migration of gastric cancer cells. Furthermore, it 
has been suggested that knockdown of CEACAM19 
leads to the inactivation of PI3K/Akt and NF-kB 
signaling pathways and to the inhibition of tumor 
growth in vivo, as measured by xenograft 
experiments in mice (Zhao et al., 2018). 
Penile cancer 
Prognosis 
Differential expression levels of CEACAM19 have 
been shown in penile cancer cases, with some 
cancerous tissues exhibiting low and others 
exhibiting higher expression levels, compared to 
normal ones. Overexpression of CEACAM19 has 
been associated with distant and lymph node 
metastasis in penile cancer and with unfavorable 
cancer-specific survival of patients, but its 
prognostic significance is not independent from 
other predictors of survival. Moreover, it has been 
shown that knockdown of CEACAM19 in penile 
cancer cell lines leads to decreased cell growth and 
that it suppresses colony formation. CEACAM19 
knockdown has also been related to the decrease of 
SMAD2/3 signaling pathway activity and inhibition 
of MMP2 and MMP9 secretion, which are both 
associated with invasion and metastasis. 
Consequently, it has been observed that migration 
and invasion abilities of the Pen11 cancerous cells 
were suppressed after CEACAM19 knockdown (Hu 
et al., 2019). 
Lung adenocarcinoma 
Prognosis 
Kobayashi et al. (2012) examined whether some 
members of the CEACAM gene family could be 
used as surrogate markers for tyrosine kinase 
inhibitor (TKI) sensitivity in lung adenocarcinoma 
patients. The examined members of the family 
included CEACAM3, CEACAM5, CEACAM6, 
CEACAM7, and CEACAM19. The expression 
patterns of all these genes were found to be 
associated with TKI sensitivity, in microarray 
analysis. Moreover, the immunoreactivity of the 
CEACAMs examined was shown to be significantly 
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higher in patients carrying EGFR mutations than in 
those carrying the wild-type gene. CEACAM19 
immunoreactivity was not found to present 
statistically significant association with 
clinicopathological parameters of lung 
adenocarcinoma patients, such as age, sex, tumor 
size, stage of the disease, and lymph node metastasis. 
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